Darnytsia Registers Medicine in New Zealand for Comprehensive Treatment of Heart and Kidney Failure

Darnytsia Pharmaceutical Company has registered a medicinal product in New Zealand, which is used for the comprehensive treatment of acute and chronic heart failure, acute and chronic kidney failure, nephrotic syndrome, liver diseases, and arterial hypertension.

New Zealand is a country with very strict regulations and high standards for the quality of medicinal products. The fact that Darnytsia's medicine has passed the rigorous registration process in this country once again proves that Ukrainian medicines are on par with global standards in terms of safety, quality, and efficacy.

It is worth noting that in June last year, Darnytsia shipped one of its products to  Australia. Meanwhile, in May 2023, it registered a medicinal product for the treatment of heart and kidney failure in Singapore, and in January 2024 – in Poland.

"Despite the challenges of the full-scale war, we continue to expand our export horizons. Today, Darnytsia medicines are exported to Europe and countries in the Asia-Pacific region. The list of countries will continue to grow as our medicines are safe, effective, efficient, and fully comply with the requirements of the most stringent global regulations," says Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company.